Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer
23 June 2021
ImmunicumAnnounces Enrollment of First Patient in Phase IALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer
- First study evaluating cancer relapse vaccine candidate DCP-001 in patients with solid tumors-
Immunicum AB (publ) today announcedthat the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company’s lead cancer relapse vaccine candidate, in High-Grade Serous Ovarian Cancer (HGSOC) patients following primary standard of care treatment.The ALISON study is carried out by Professor Hans Nijman and his research group in Groningen, the Netherlands, and investigates the ability of DCP-001 to trigger the immune system to control cancer cells that may have remained in the body after surgery and treatment with chemotherapy in order to prevent or reduce tumor reccurence.This is the first study using Immunicum’s cancer relapse vaccine approach to target a solid tumor indication and will evaluate the safety, feasibility and immunogenicity of DCP-001.
“The start of the Phase I ALISON study with the first patient enrolled marks an important milestone in our clinical development strategy, as ovarian cancer is a completely new indication for Immunicum and the study is the first evaluation of DCP-001 in a solid tumor indication,” commented Jeroen Rovers, Chief Medical Officer at Immunicum. “Other immunotherapies such as checkpoint inhibitors have shown relatively low responses in ovarian cancer. This study builds on our promising preclinical data showing significant reduction in tumor growth following DCP-001 administration and will further evaluate the immunogenicity of our cancer relapse vaccine candidate in patients with solid tumors for the first time.”
Hans W Nijman, MD, PhD, Principal Investigator of the ALISON study and Professor at University Medical Center in Groningen, the Netherlands, added: “Tumors tend to develop ways that allow them to evade the body’s immune response against them, hence making the tumors resistant to many therapies. Immunicum’s relapse vaccine candidate contains allogeneic dendritic cells that can boost various key elements of the immune system against multiple tumor antigens, potentially making it a vital component in the fight against tumor recurrence and clinical relapse in ovarian cancer patients.”
The Phase I ALISON study is a single-center, open-label study evaluating safety and efficacy of DCP-001 in High-Grade Serous Ovarian Cancer (HGSOC) patients. HGSOC is a unique type of epithelial cancer that is characterized by the loss of function of the tumor suppressor protein, p53, which can lead to chemotherapy resistance and disease relapse. The vaccination regimen with DCP-001 will be scheduled after standard of care treatment, which includes chemotherapy either before or after debulking surgery, and will start 6 weeks following the last cycle of chemotherapy. Patients will receive 4 bi-weekly vaccinations with 25 million cells per DCP-001 vaccination and 2 additional booster vaccinations with 10 million cells per vaccination. Patient follow-ups will be conducted for 24 months. The primary endpoint of the study is change from baseline of DCP-001 vaccine antigen-specific T cells in peripheral blood after treatment. Key secondary endpoints include safety and tolerability after repeated DCP-001 dosing as well as recurrence free survival (RFS) and overall survival (OS) during the follow-up period.
DCP-001 is an “off-the-shelf”, cell-based, cancer relapse vaccine candidate that is based on a proprietary cell line and manufacturing process developed by Immunicum to treat cancer patients with solid and blood-borne tumors. The cancer vaccine candidate contains endogenous tumor-associated antigens that are highly immunogenic and can recruit as well as activate the patient’s own immune cells to prime specialized immune cells called T cells to target multiple tumor antigens and attack the tumor. DCP-001 has the potential to boost the immune system to control residual disease and prevent or reduce tumor recurrence. It has already shown an excellent safety profile in clinical studies and is currently also being evaluated in an ongoing international Phase II clinical trial in acute myeloid leukemia (AML) patients.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
Telephone: +31 713 322 627
Head of Investor Relations & Corporate Communication
Telephone: +46 8 732 8400
Eva Mulder and Sophia Hergenhan
Telephone: +49 175 222 57 56
ABOUT IMMUNICUM AB (PUBL)
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Leasinvest Real Estate SA: Publication of a transparency notification26.7.2021 18:00:00 CEST | Press release
PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 26 July 2021 issued by AG Insurance, shows that both a passive threshold overrun and a drop below the minimum threshold took place, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AG Insurance in Leasinvest Real Estate has therefore decreased to 2.58% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun - Drop below the minimum threshold NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress Ageas SA/NV Rue du Marquis 1, 1000
PRESS RELEASE: BIGBEN: Q1 2021/22 Sales26.7.2021 17:50:00 CEST | Press release
Bigben Press release Lesquin, 26 July 2021 18:00 hrs Q1 2021/22 Sales: 56.7 M€ (+2.8%) High sales historyforNacon Gaming Favourable base effect for Audio-Telco Confirmation of FY 2021/22 and FY 2022/23 targets IFRS – M€ Sales 2021/2022 2020/2021 Change 1st Quarter Nacon Gaming Bigben Audio-Telco 56.7 33.7 23.0 55.2 38.0 17.2 +2.8% -11.3% +33.9% Non audited data In Q1 FY 2021/22 (April 1 to June 30, 2021), Bigben posted sales of €56.7 million, an increase of 2.8%, driven by Audio-Telco, which benefited from a favourable comparison basis, unlike the Nacon Gaming business unit, demonstrating the benefit from being present across several markets. NACON GAMING In Q1 2021/22, Nacon achieved sales of 33.7 M€, down 11.3% on Q1 2020/2021. Despite an unfavourable comparison basis, the back catalogue showed a positive momentum. Games: The segment posted sales of 12.2 M€, down 16.0% compared with Q1 2020/21, whose back catalogue sales had been boosted by 340% by lockdown. The back catalogue demons
PRESS RELEASE: NACON: Q1 2021/22 Sales26.7.2021 17:45:00 CEST | Press release
Press release Lesquin, 26 July 2021 18 :00hrs Q1 2021/22 Sales : 33.7 M€(-11.3%) High comparison basisBack catalogue résilience Confirmation ofFY 2021/22 and FY 2022/23targets IFRS – M€ Sales Non audited data 2021/2022 2020/2021 Change 1st Quarter Games Accessories Others(1) 33.7 12.2 20.6 0.9 38.0 14.5 22.5 0.9 - 11.3% -16.0% -8.8% + 0.5% (1)Mobile and Audio sales. In Q1 2021/22 (from 1 April to 30 June 2021), Nacon achieved sales of 33.7 M€, down 11.3% compared to Q1 2020/2021. Despite an unfavourable comparison basis, the back catalogue showed a positive momentum. GAMES The video games business posted sales of 12.2 M€, down 16.0% compared with Q1 2020/21, when back catalogue sales were boosted 340% by lockdown. However the good performance of the back catalogue demonstrated its resilience with sales of 9.2 M€ against 10.8 M€ in Q1 2020/21 during the first lockdown, to be compared with 2.4 M€ in Q1 2019/20. The Roguebook (81% positive reviews on Steam) and Pro Cycling Management / To
Agfa-Gevaert: Share buyback program – regulated information26.7.2021 17:40:00 CEST | Press release
Mortsel, Belgium – July 26, 2021 – 5:40 p.m. CET Within the framework of the share buyback program which was announced in the press release of March 10, 2021, Agfa-Gevaert NV proceeded with the purchase of own shares on the market of Euronext Brussels. The authorization to acquire own shares was granted to the Board of Directors by the Extraordinary General Meeting of Shareholders of May 12, 2020. Agfa-Gevaert NV has requested a financial intermediary to repurchase Agfa-Gevaert shares for a maximum amount of 50,000,000 Euro on its behalf under the terms of an initial discretionary mandate agreement with validity until March 31, 2022, effective as from April 1, 2021. As a result of a decision of the Board of Directors, the company, by notarial deed dated June 22, 2021, cancelled a total of 1,996,884 treasury shares. This decision was taken in accordance with the authorization granted to the Board of Directors by the Extraordinary General Meeting of Shareholders on May 12, 2020. As a con
Leading Edge Materials Announces Filing of Preliminary Economic Assessment Report for Woxna Graphite Anode Project26.7.2021 14:30:00 CEST | Press release
Vancouver, July 26, 2021 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) is pleased to announce that the technical report for its Woxna Graphite project (the “Project”) titled “NI 43-101 Technical Report – Woxna Graphite” with effective date June 9, 2021, has been filed under the Company’s profile on SEDAR today (the “Report” or “PEA”). The Report supports the disclosure in the Company’s news release dated June 9, 2021. All figures in the Report are US dollars unless otherwise specified. The news release on June 9, 2021, presented these highlights of the Report: Main PEA Highlights The PEA indicates the potential viability of a Swedish operation producing battery grade graphite anode material utilizing an existing graphite mine and concentrator with the addition of a value-add processing facility offsite;The proposed process route in the PEA uses a thermal purification process which, combined with access
Cavotec wins key motorised cable reel order for advanced container cranes in Japan26.7.2021 09:00:00 CEST | Press release
Cavotec has won a key order for its innovative motorised cable reel systems for integration onto advanced rail-mounted gantry cranes at the Port of Tokyo – a project that highlights Cavotec’s position as a trusted supplier of mission-critical systems at ports and terminals. “Given the complexity of these high-end cranes and their demanding operational environment, this is an excellent reference for us as we continue to grow in Japan and the wider region,” says Robin Shang, Cavotec Regional Sales Director Ports & Maritime. Cavotec will supply motorised cable reel systems for eight automated rail-mounted gantry (ARMG) cranes at the Wan Hai Tokyo Oi5 terminal, a major global container handling hub. The cable reels will ensure the cranes meet demanding performance requirements due to surging container volumes. Working closely with Chin Pan engineering group, Cavotec is scheduled to complete the delivery of the systems in early 2023. Previously, Chin Pan has fitted two ARMGs cranes successf
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme26.7.2021 08:44:35 CEST | Press release
Company Announcement No. 38/2021 Copenhagen, 26 July 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 19 July to 23 July 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement1,781,412222,947,59319 July 202120,000125.242,504,78020 July 202115,510125.551,947,26